|
|||||
|
|
Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor,tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label,multicenter, post‐marketing clinical study |
|
| Authors: | Yasuo Terauchi Hisataka Fujiwara Yuji Kurihara Hideki Suganami Masahiro Tamura Masayuki Senda Ryoji Gunji Kohei Kaku |
| Abstract: | |
| Keywords: | Glucagon‐like peptide‐1 receptor Sodium– glucose cotransporter 2 inhibitor Type 2 diabetes mellitus |